Neurizon Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Neurizon Therapeutics has a total shareholder equity of A$10.2M and total debt of A$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are A$11.1M and A$896.6K respectively.
Key information
0%
Debt to equity ratio
AU$0
Debt
| Interest coverage ratio | n/a |
| Cash | AU$10.73m |
| Equity | AU$10.23m |
| Total liabilities | AU$896.61k |
| Total assets | AU$11.12m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: ECQ0's short term assets (A$11.1M) exceed its short term liabilities (A$896.0K).
Long Term Liabilities: ECQ0's short term assets (A$11.1M) exceed its long term liabilities (A$649.0).
Debt to Equity History and Analysis
Debt Level: ECQ0 is debt free.
Reducing Debt: ECQ0 has no debt compared to 5 years ago when its debt to equity ratio was 4.4%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ECQ0 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: ECQ0 has sufficient cash runway for 1.3 years if free cash flow continues to reduce at historical rates of 3% each year.